This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc., a subsidiary of Sumitomo Pharma Co., Ltd., is headquartered in the United States and operates primarily in North America. Founded in 2005, the company has established itself within the pharmaceutical industry, focusing on innovative treatments in areas such as central nervous system disorders, oncology, and infectious diseases. With a commitment to research and development, Sumitomo Pharma America offers unique products that address unmet medical needs, leveraging advanced technologies and scientific expertise. The company has achieved significant milestones, including strategic partnerships and the successful launch of several key therapies, solidifying its position in the competitive pharmaceutical landscape. Through its dedication to improving patient outcomes, Sumitomo Pharma America continues to make a notable impact in the healthcare sector.
DitchCarbon Score
How does Sumitomo Pharma America, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sumitomo Pharma America, Inc.'s score of 36 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sumitomo Pharma America, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Sumitomo Pharma Co., Ltd., which operates at a cascade level of 2. Consequently, any climate commitments or reduction targets may be influenced by the parent company's initiatives. While there are no documented reduction targets or climate pledges specific to Sumitomo Pharma America, Inc., it is important to note that the overarching climate strategies and performance metrics are likely derived from Sumitomo Pharma Co., Ltd. This includes potential commitments to the Science Based Targets initiative (SBTi) and other sustainability frameworks, although specific details on these initiatives are not provided. In summary, while Sumitomo Pharma America, Inc. does not currently disclose emissions data or specific reduction targets, it is positioned within a corporate structure that may align with broader climate commitments from its parent company, Sumitomo Pharma Co., Ltd. Further information on their climate strategies would be necessary to provide a comprehensive overview of their environmental impact and commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 41,805,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | - | - |
| Scope 2 | 38,906,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 35,270,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sumitomo Pharma America, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
